Roivant sets date for PHocus Phase 2 reveal

Roivant (ROIV) and its Pulmovant subsidiary have scheduled the first public presentation of topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease. The data will be shared at the European Respiratory Society International Congress 2026 on Tuesday, September 8, 2026. The companies are positioning the ERS appearance as the primary venue for unveiling the Phase 2 topline findings in this patient population.

The PHocus study focuses on mosliciguat in pulmonary hypertension associated with interstitial lung disease, a form of pulmonary hypertension linked with lung tissue abnormalities. The announcement centers on when and where these initial Phase 2 topline results will be communicated, without including any numerical outcomes, efficacy measures, or safety details from the trial.

The topline PHocus results will be presented in a formal scientific session at the ERS International Congress. The session is scheduled for 12:15 CEST on September 8, 2026, corresponding to 6:15 a.m. Eastern Time. This time slot places the presentation within the broader Congress agenda, highlighting the data within a respiratory and pulmonary medicine context.

The presenter will be Marc Humbert, MD, PhD, a Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. His role underscores that the results will be communicated by a specialist in pulmonary hypertension within an international scientific forum.

In parallel with the scientific disclosure, Roivant plans to host an investor call and webcast on Tuesday, September 8, 2026. Several published notices indicate that this investor event is scheduled to begin at 8:00 a.m. Eastern Time. The call is intended to provide investors with an opportunity to hear management discuss the topline PHocus results after the ERS presentation.

Roivant has stated that a replay or archived webcast of the investor call will be made available on the company’s investor website after the live event. This will allow stakeholders who cannot join at the scheduled time to review the company’s prepared remarks and any accompanying discussion of the topline data.

The current communications from Roivant and Pulmovant focus on logistics and timing rather than clinical detail. They establish the date, venue, and format for disclosure of topline Phase 2 PHocus results but do not include any reported numbers or qualitative assessments of mosliciguat’s performance in PH-ILD. No efficacy endpoints, safety findings, or statistical outcomes are described in the available announcements.

As a result, the significance of the forthcoming PHocus topline data for mosliciguat’s development program remains to be defined by the actual results that will be presented at ERS 2026 and discussed on the same-day investor call. For now, the key development is the formal scheduling of these disclosures and the identification of the presenting investigator and event times.